viewValiRx PLC

Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

George Morris, chief operations officer of ValiRx Plc (LON:VAL), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly.

He says by nature they're detailed and complex but he hopes they'll be completed shortly and he's looking to undertake the trial early next year.

''[There's] significant interest in all the relevant areas most definitely'', Morris adds.

He also updates on developments within the rest of the portfolio including VAL 201 which is still in a phase I/II trial  for patients affected by hormone- sensitive and hormone-resistant prostate cancer.

Quick facts: ValiRx PLC

Price: 14.75 GBX

Market: AIM
Market Cap: £7.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read